drugset / Trial / NCT04555213
A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase Ib, open-label, multicenter, study of NOX66, given rectally to hospitalized patients with moderate systemic illness due to COVID-19 infection at high risk of developing severe sepsis / septic shock.
Timeline
- Start
- 2020-09-30
- Primary completion
- 2021-08-10
- Completion
- 2021-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NOX66 | Small molecule | 400 mg | Rectal |
| Subject | NOX66 | Small molecule | 600 mg | Rectal |
| Subject | NOX66 | Small molecule | 800 mg | Rectal |
| Subject | NOX66 | Small molecule | 1200 mg | Rectal |
| Subject | NOX66 | Small molecule | 1800 mg | Rectal |